Table 1.
Baseline Characteristics of the Patients, Stratified by the Change in the AQLQ Score at 4 Months.
| Characteristic | Responders | Non-responders | p value |
|---|---|---|---|
| n | 6 | 5 | |
| Age (years) | 59.67±17.42 | 53.4±23.31 | 0.62 |
| Gender (male/female) | 3/3 | 0/5 | |
| BMI (kg/m2) | 20.98±1.67 | 24.26±6.63 | 0.27 |
| Disease duration (years) | 26.5±17.83 | 16±9.59 | 0.27 |
| Smoking index | 165±159.1 | 80±80 | 0.67 |
| FeNO level (ppb) | 112.8±69.14 | 57.18±39.45 | 0.20 |
| Blood eosinophil count (/µL) | 590.3±346.5 | 467±303.7 | 0.55 |
| Blood neutrophil count (/µL) | 4,082±510.5 | 4,543±1,063 | 0.69 |
| Total serum IgE (IU/mL) | 137.3±99.5 | 162.2±207.3 | 0.80 |
| FEV1 (% predicted) | 65.3±20.7 | 75.6±15.1 | 0.38 |
| FEV1 (L) | 1.46±0.61 | 1.49±0.54 | 0.94 |
| AQLQ overall score | 4.6±0.76 | 4.6±0.76 | 0.88 |
| Asthma VAS score (cm) | 3.3±3.61 | 5.46±3.32 | 0.33 |
| OCS use (%) | 1 (16.7) | 2 (40) | |
| High-dose ICS use (%) | 6 (100) | 5 (100) | |
| LABA use (%) | 6 (100) | 5 (100) | |
| LAMA use (%) | 3 (50) | 2 (40) | |
| LTRA use (%) | 5 (83.3) | 4 (80) | |
| Theophylline use (%) | 4 (66.7) | 4 (80) | |
| Use of other biologics within previous three months (%) | 1, omalizumab (16.7) | 1, omalizumab (20) |
Values are presented as the mean±SD.
AQLQ: Asthma Quality of Life Questionnaire, FEV1: forced expiratory volume in 1 s, OCS: oral corticosteroid, ICS: inhaled corticosteroid, LABA: long-acting beta-agonists, LAMA: long-acting muscarinic antagonists, LTRA: leukotriene receptor antagonists